-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。目標株価を40ドル引き上げ、325ドルとします。これは、2027年の1株当たり利益（EPS）10.78ドル（従来予想9.48ドル）の約30倍に相当します。2026年のEPSは7.60ドルから9.34ドルに引き上げました。第1四半期の業績は高いハードルをクリアしました。AWSは前年同期比28%増となり、2025年第4四半期から4ポイント加速し、年間売上高は3年前の850億ドルから1500億ドルに達しました。今後さらなる成長が見込まれ、AWSは2026年末までに30%台後半の成長率を達成する可能性があります。これは、同社の受注残高3640億ドル（前四半期比49%増）に支えられています。この数字には、最近発表された1000億ドル超のAnthropicとの契約はまだ含まれていません。成長を牽引しているのは、カスタムシリコン（Trainium）とCPUインフラストラクチャ（Graviton）の両方における需要の急増であり、後者はAIが推論とエージェントワークロードへと移行し続けていることを反映している。小売部門では、AMZNが日用品と食料品の市場浸透を深めるにつれ、販売台数はパンデミック時代の水準に戻った。AMZNは第1四半期に過去最高の13.1%の営業利益率を記録し、Amazon Leo関連の生産・立ち上げコストが資本化される2026年下半期には、さらに利益率が上昇すると見込んでいる。
Related Articles
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.
$FE
Sectors
Sector Update: Consumer
Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.
$LW
Australia
Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug
The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%
$AZN